USA - NASDAQ:STSA - US80405P1075 - Common Stock
ChartMill assigns a Buy % Consensus number of 76% to STSA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating | 
|---|---|---|---|
| 2023-04-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral | 
| 2023-03-30 | Mizuho | Reiterate | Neutral | 
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy | 
| 2022-11-15 | Mizuho | Downgrade | Buy -> Neutral | 
| 2022-11-15 | SVB Leerink | Downgrade | Outperform -> Market Perform | 
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy | 
| 2022-10-10 | SVB Leerink | Upgrade | Market Perform -> Outperform | 
| 2022-09-21 | HC Wainwright & Co. | Maintains | Buy | 
| 2022-08-31 | Ladenburg Thalmann | Initiate | Buy | 
| 2022-08-25 | JonesTrading | Initiate | Buy | 
| 2022-05-13 | Mizuho | Maintains | Buy | 
| 2021-06-22 | Mizuho | Upgrade | Neutral -> Buy | 
| 2021-05-12 | SVB Leerink | Maintains | Market Perform | 
| 2021-03-02 | Credit Suisse | Upgrade | Underperform -> Neutral | 
11 analysts have analysed STSA and the average price target is 2.04 USD. This implies a price increase of 85.45% is expected in the next year compared to the current price of 1.1.
The consensus rating for Satsuma Pharmaceuticals Inc (STSA) is 76.3636 / 100 . This indicates that analysts generally have a positive outlook on the stock.